Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company focused on mebufotenin-based therapies for treatment-resistant depression and related psychiatric conditions. As a foreign private issuer, GH Research submits annual reports on Form 20-F and furnishes current information on Form 6-K.
In its Form 6-K current reports, the company provides updates on quarterly and interim financial results, business developments, and clinical progress. These filings often include condensed consolidated interim financial statements prepared under IFRS, detailing research and development expenses, general and administrative expenses, finance income and expense, and accumulated deficits typical of an R&D-focused enterprise. Balance sheet information in these filings outlines cash, cash equivalents, other financial assets, marketable securities, and equity components such as share capital and additional paid-in capital.
GH Research also uses Form 6-K to furnish press releases and investor materials describing milestones in its GH001 and GH002 programs, including Phase 2b and Phase 2a trial results, open-label extension data, safety and tolerability profiles, and regulatory interactions with the U.S. Food and Drug Administration. Additional 6-Ks announce participation in scientific congresses such as ECNP, ASCP, ISBD, and ACNP, where abstracts and presentations related to GH001-TRD-201 and other trials are shared.
Through this filings page, users can access GH Research’s SEC-submitted documents as they are made available from EDGAR. AI-powered tools on the platform can help summarize lengthy financial and clinical disclosures, highlight key points from interim results, and make it easier to track how GH Research’s development programs and capital position evolve across reporting periods.
GH Research PLC (NASDAQ: GHRS) filed a Form 6-K reporting that it has submitted a complete response to the U.S. FDA concerning the clinical hold on its Investigational New Drug (IND) application for GH001. The submission was made in June 2025 and disclosed to investors via a press release dated 20 June 2025 (attached as Exhibit 99.1).
The filing does not disclose FDA feedback, timelines, or whether the hold will be lifted. Management expressly states it will not update the press release or forward-looking statements, underscoring regulatory uncertainty. No financial statements, earnings metrics, or other operational updates accompany the filing.
Investor takeaway: The response filing is an incremental regulatory step that could enable clinical trials of GH001 to resume if the FDA is satisfied. However, material impact remains contingent on the FDA’s decision; therefore, the risk profile for GHRS is largely unchanged until further notice.